{"id":1043,"date":"2018-09-03T10:05:46","date_gmt":"2018-09-03T08:05:46","guid":{"rendered":"http:\/\/celltrend.oder.media\/?page_id=1043"},"modified":"2025-10-29T11:46:39","modified_gmt":"2025-10-29T10:46:39","slug":"pots-cfs-me-sfn","status":"publish","type":"page","link":"https:\/\/www.celltrend.de\/en\/pots-cfs-me-sfn\/","title":{"rendered":"POTS &#8211; CFS\/ME  &#8211; SFN &#8211; Long Covid"},"content":{"rendered":"<h4><span style=\"color: #ff0000;\"><a style=\"color: #ff0000;\" href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2025\/10\/Request-form-11-2025.pdf\">Request form<\/a><\/span><\/h4>\n<h4><span style=\"color: #ff0000;\"><a style=\"color: #ff0000;\" href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2025\/06\/Patient-Instructions.pdf\">information about sample collection, shipping, invoicing, sending the results &#8230;click here!<\/a><\/span><\/h4>\n<hr \/>\n<h2>POTS\/ Long Covid-diagnostics<\/h2>\n<p>A test panel for POTS patients is available. In addition to auto-antibodies against the Beta-1 adrenergic receptor, auto-antibodies against the Beta-2adrenergic receptor, auto-antibodies against the muscarinic cholinergic Receptor 3 (M3) and auto-antibodies against the muscarinic cholinergic Receptor 4 (M4) we will test muscarinic cholinergic Receptor 1 (M1), muscarinic cholinergic Receptor 2 (M2), muscarinic cholinergic Receptor 5 (M5), as well as Alpha-1 adrenergic receptor auto-antibodies and Alpha-2 adrenergic receptor auto-antibodies. Prof. Dr. Kem, University of Oklahoma Health Sciences Center and VA Medical Center, described the <a href=\"\/wp-content\/uploads\/2018\/09\/2018-J-Am-Heart-Assoc-Oklahoma-Kem-AT1R-Ab-POTS.pdf\" rel=\"noopener\" download=\"\">occurrence of AT1R antibodies in sera from POTS patients<\/a>. Therefore, the CellTrend POTS test profile has been extended to AT1R-Ab testing. The costs for Beta-1, Beta-2 and M1-M5, ATR1 and ETAR are \u20ac 27,- ($ 33,-) each, for Alpha-1 and-2 \u20ac 112,- ($ 139,-) each and in total \u20ac 467,- ($ 575,-). It is also possible to send samples (IMPORTANT: Only send the seperated sera after centrifugation, not the entire unprocessed blood or plasma sample) for auto-antibody POTS-diagnostic to the CellTrend lab.<\/p>\n<ul>\n<li>Angiotensin-II-Receptor-1 (AT1R) IgG-auto-antibodies<\/li>\n<li>Angiotensin-II-Receptor-2 (AT2) IgG-auto-antibodies<\/li>\n<li>Endothelin-Receptor-A (ETAR) IgG-auto-antibodies<\/li>\n<li>Endothelin-Receptor-B (ETB) IgG-auto-antibodies<\/li>\n<li>Beta-1 adrenergic receptor auto-antibodies<\/li>\n<li>Beta-2 adrenergic receptor auto-antibodies<\/li>\n<li>Muscarinic cholinergic (M1) receptor auto-antibodies<\/li>\n<li>Muscarinic cholinergic (M2) receptor auto-antibodies<\/li>\n<li>Muscarinic cholinergic (M3) receptor auto-antibodies<\/li>\n<li>Muscarinic cholinergic (M4) receptor auto-antibodies<\/li>\n<li>Muscarinic cholinergic (M5) receptor auto-antibodies<\/li>\n<li>Alpha-1 adrenergic receptor auto-antibodies<\/li>\n<li>Alpha-2 adrenergic receptor auto-antibodies<\/li>\n<\/ul>\n<h4><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2025\/10\/Request-form-11-2025.pdf\"><span style=\"color: #ff0000;\">Request form<\/span><\/a><\/h4>\n<h2>CFS-diagnostics<\/h2>\n<p>Together with Prof. Dr. Carmen Scheibenbogen, University Hospital Charite Berlin, CellTrend developed a straightforward Immuno-Assay for the diagnostic\u00a0 of the Chronic fatigue syndrome\/myalgic encephalomyelitis (CFS\/ME). The results have been published in\u00a0<a href=\"\/wp-content\/uploads\/2018\/09\/Brain-Behav-Immun.pdf\" rel=\"noopener\" download=\"\">Brain, Behavior, and Immunity<\/a>.\u00a0\u00a0A first clinical trial for treatment has been successfully completed and is published in <a href=\"\/wp-content\/uploads\/2018\/09\/2018-PLoS-One-Berlin-Scheibenbogen-CFSME-Treatment-IA.pdf\" rel=\"noopener\" download=\"\">PLoS ONE<\/a> (Scheibenbogen C. et al 2018).<\/p>\n<p>Auto-antibodies against the Beta-2 adrenergic receptor, auto-antibodies against the muscarinic cholinergic Receptor 3 (M3) and auto-antibodies against the muscarinic cholinergic Receptor 4 (M4) are elevated in a subset of 20-30% of all patients suffering from Chronic fatigue syndrome\/myalgic encephalomyelitis (CFS\/ME). Tests are available in our lab, it is possible to send samples (IMPORTANT:\u00a0Only send the seperated sera after centrifugation, not the entire unprocessed blood or plasma sample) for auto-antibody CFS-diagnostic to the CellTrend lab. The costs per biomarker are \u20ac 27,- ($ 33,-) and in total \u20ac 108,- ($ 132,-).<\/p>\n<ul>\n<li>Beta-1 adrenergic receptor auto-antibodies<\/li>\n<li>Beta-2 adrenergic receptor auto-antibodies<\/li>\n<li>Muscarinic cholinergic (M3) receptor auto-antibodies<\/li>\n<li>Muscarinic cholinergic (M4) receptor auto-antibodies<\/li>\n<\/ul>\n<h4><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2025\/10\/Request-form-11-2025.pdf\"><span style=\"color: #ff0000;\">Request form<\/span><\/a><\/h4>\n<h2>Small Fiber Neuropathy (SFN)<\/h2>\n<p>Small Fiber Neuropathy (SFN) is a subtype of neuropathy that is characterized by the selective involvement of non-myelinated or thinly-myelinated sensory fibers is marked. Its pathogenesis includes a wide range of immune-mediated, metabolic, toxic, hereditary and genetic disorders. SFN has been described in connection with Sj\u00f6gren&#8217;s syndrome, celiac disease, systemic lupus erythematosus, rheumatoid arthritis, diabetes mellitus type 1, inflammatory bowel disease, sarcoidosis and paraneoplastic syndrome. Some data also suggest an association with Hashimoto&#8217;s thyroiditis. Clinical symptoms of SFN can manifest as isolated sensory disorders as well as isolated autonomic disorders.<\/p>\n<p>Intravenous immunoglobulin therapy (IVIG) showed a significant effect in treating patients with autoimmune mediated SFN in two large retrospective studies with comparable response rates (77% and 83% of patients).<\/p>\n<p>Autoantibodies against fibroblast growth factor receptor-3 (FGFR3-IgG) and tri-sulfate heparin di-saccharide (TSHDS-IgM) are elevated in SFN. A clinical study is currently evaluating the efficacy of IVIG administration in FGFR3-Ab and TSHDS-Ab positive patients.<\/p>\n<ul>\n<li>FGFR3 auto-antibodies<\/li>\n<li>TSHDS auto-antibodies<\/li>\n<\/ul>\n<h4><span style=\"color: #ff0000;\"><a style=\"color: #ff0000;\" href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2025\/10\/Request-form-11-2025.pdf\">Request form<\/a><\/span><\/h4>\n<h2>Important Publications<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2016-Brain-Behav-Immun-Scheibenbogen-CFS.pdf\">2016 Brain Behav Immun Scheibenbogen CFS<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2017-Int-J-Cardiol-Bergen-Giil-GPCR-Antibody-Heart-failure-full-text.pdf\">2017 Bergen &#8211; Giil &#8211; GPCR-Antibody &#8211; Heart failure<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2017-J-Alzheimers-Dis-Bergen-Giil-Ab-Panel-Alzheimer-full-text.pdf\">2017 Bergen &#8211; Giil &#8211; Ab Panel &#8211; Alzheimer <\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2018-Frontiers-in-Bioscience-Luckenwalde-Meyer-Antibody-against-GPCR-Review-4698.pdf\">2018 Frontiers in Bioscience &#8211; Antibody against GPCR<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2018-Naturecommunication-Luebeck-Riemekasten-GPCR-Ab.pdf\">2018 nature communications &#8211; L\u00fcbeck &#8211; Riemekasten &#8211; GPCR-Ab<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2018-PLoS-One-Berlin-Scheibenbogen-CFSME-Treatment-IA.pdf\">2018 PLoS One &#8211; Berlin &#8211; Scheibenbogen &#8211; CFSME Treatment IA<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2019-AACR-Ikeda-Matsumoto-Japan-HPV-POTS-aacr-v2-id1014.pdf\">2019 AACR- Ikeda &#8211; Matsumoto &#8211; Japan &#8211; HPV POTS\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2019-Hum-Immunol-Reinsmoen-Los-Angeles-Non-HLA-Antibody-Transplantation-Review.pdf\">2019 Hum Immunol &#8211; Reinsmoen &#8211; Los Angeles &#8211; Non-HLA Antibody Transplantation<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2019-JAHA-Gunning-Toledo-POTS-JAHA.119.0136022.pdf\">2019 JAHA &#8211; Gunning &#8211; Toledo &#8211; POTS\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2019-Kidney-Int-France-Lefaucheur-Kidney-Transplantation-AT1R-Ab.pdf\">2019 Kidney Int &#8211; France &#8211; Lefaucheur &#8211; Kidney Transplantation AT1R-Ab<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2020-Aging-Duesseldorf-Boege-b1-adr-R-Ab-M5R-Ab-Periodontitis-aging-v12i16-103864.pdf\">2020 D\u00fcsseldorf &#8211; Boege &#8211; b1-adr-R-Ab M5R-Ab &#8211; Periodontitis &#8211; aging<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2020-Autoimmune-dysautonomia-Tel-Aviv-Shoenfeld-Review.pdf\">2020 Autoimmune dysautonomia &#8211; Tel-Aviv &#8211; Shoenfeld<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2020-Brain-Behaviour-Immunity-Health-Uppsala-Bergquist-CFS-1-s2.0-S2666354620300727-main.pdf\">2020 Brain Behaviour Immunity &#8211; Health &#8211; Uppsala &#8211; Bergquist CFS\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2021-Journal-of-Autoimmunity-Israel-Shoenfeld-SBI-dysautonomia.pdf\">2021 Journal of Autoimmunity &#8211; Israel &#8211; Shoenfeld &#8211; SBI dysautonomia<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2021\/04\/2021-Trends-Pharmacol-Sci-Havard-Kruse-Review-Autoantibodies-as-endogenous-modulators-of-GPCR-signaling.pdf\">2021 Havard &#8211; Kruse &#8211; Autoantibodies as endogenous modulators of GPCR signaling<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2022\/03\/2022-Nature-Communications-COVID-19.pdf\">2022 Nature Communications-COVID-19<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2023\/03\/2023-Autoimmunity-Reviews-Report-of-the-fourth-Symposium-about-Autoantibodies-targeting-G-protein-coupled-receptors-in-Luebeck.pdf\">2023 Autoimmunity Reviews &#8211; Report of the fourth Symposium about Autoantibodies targeting G protein-coupled receptors in L\u00fcbeck<\/a><\/li>\n<li><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1568997223001799?via%3Dihub\">2023 Long COVID Symptoms<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2025\/10\/2025-Frontiers-in-Immunology-Padua-Vadori-AT1R-ETAR-STEMI-Prognostic-Role-fcvm-12-1515693.pdf\">2025 Frontiers in Immunology &#8211; Padua &#8211; Vadori &#8211; AT1R ETAR STEMI Prognostic Role<\/a><\/li>\n<li><a href=\"https:\/\/www.celltrend.de\/wp-content\/uploads\/2025\/10\/2025-frontiers-in-immunology-Banasik-AT1R-Kidney-Transplantation.pdf\">2025 frontiers in immunology &#8211; Banasik &#8211; AT1R Kidney Transplantation<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Request form information about sample collection, shipping, invoicing, sending the results &#8230;click here! POTS\/ Long Covid-diagnostics A test panel for POTS patients is available. In addition to auto-antibodies against the Beta-1 adrenergic receptor, auto-antibodies against the Beta-2adrenergic receptor, auto-antibodies against the muscarinic cholinergic Receptor 3 (M3) and auto-antibodies against the muscarinic cholinergic Receptor 4 (M4)&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"yst_prominent_words":[372,362,370,364,367,369,363,530,376,368,366,365,378,371],"class_list":["post-1043","page","type-page","status-publish","hentry","description-off"],"_links":{"self":[{"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/pages\/1043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/comments?post=1043"}],"version-history":[{"count":69,"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/pages\/1043\/revisions"}],"predecessor-version":[{"id":1584,"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/pages\/1043\/revisions\/1584"}],"wp:attachment":[{"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/media?parent=1043"}],"wp:term":[{"taxonomy":"yst_prominent_words","embeddable":true,"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/yst_prominent_words?post=1043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}